New drug cocktail shows promise for tough cervical cancer

NCT ID NCT07256236

Recruiting now Disease control Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a combination of two drugs, Sacituzumab tirumotecan and QL1706, in 89 women with recurrent or metastatic cervical cancer that cannot be treated with surgery or radiation. The goal is to see if the combo can shrink tumors and improve survival. Participants will receive infusions every two weeks until the cancer progresses or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab tirumotecan (SKB264) and QL1706
What this could lead to: If successful, this combination could offer a new treatment option for women with recurrent or metastatic cervical cancer, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is an early-phase, single-arm trial with no placebo group, so results are preliminary. Side effects from the drugs may be significant, and the treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

Affiliated Hospital of Jining Medical University
NOT_YET_RECRUITING

Jining, Shandong, 272113, China
Cancer Hospital of Shandong First Medical University
NOT_YET_RECRUITING

Jinan, Shandong, 250117, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350011, China
Fujian Medical University Affiliated Second Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, 362000, China
Guangxi Medical University Cancer Hospital
NOT_YET_RECRUITING

Nanning, Guangxi, 530213, China
Qilu Hospital of Shandong University
NOT_YET_RECRUITING

Jinan, Shandong, 250012, China
Qilu Hospital of Shandong University(Qingdao)
NOT_YET_RECRUITING

Qingdao, Shandong, 266011, China
Shandong Provincial Hospital
NOT_YET_RECRUITING

Jinan, Shandong, 250013, China
Shanxi Cancer Hospital
NOT_YET_RECRUITING

Taiyuan, Shanxi, 030013, China
The Affiliated Hospital of Inner Mongolia Medical University
NOT_YET_RECRUITING

Hohhot, Inner Mongolia, 010030, China
The Second Hospital of Dalian Medical University
NOT_YET_RECRUITING

Dalian, Liaoning, 116027, China
The Second Qilu Hospital of Shandong University
NOT_YET_RECRUITING

Jinan, Shandong, 250012, China
Zhangzhou Affiliated Hospital of Fujian Medical University
RECRUITING

Zhangzhou, Fujian, 363000, China
Zhujiang Hospital of Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.